Hepatitis B
Conditions
Keywords
Hepatitis B Virus, Elispot test, T cellular immune response
Brief summary
Activation of the immune system against a pathogen can be considered one of the most effective interventions in the field of infectious diseases. Transgene is developing a therapeutic vaccine TG1050 for the treatment of patients with chronic and treated Hepatitis B. This biotherapy compound is for the development of T cellular immune response in these patients in order to achieve the total elimination of infected cells. Therefore it is necessary to have measures of ways to assess accurately and reliably the presence of such a response in the study subjects.
Interventions
BIOLOGICALblood samples are performed to measure active T cellular immune response during a routine visit
During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV. The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit.
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Man or woman aged ≥18 years old. Patients with chronic hepatitis B regardless of the genotype. * treated with nucleotide analogs approved for the treatment of hepatitis B. * or untreated. * with a positive or negative antigen HBe * regardless of the level of transaminases. Patients with a history of HBV infection (recovered) with seroconversion of antigen HBs spontaneously or under treatment. Patient with a general state ranging 0 or 1 on the ECOG scale (Eastern Cooperative Oncology Group) Patient who signed the informed consent Patient with a social security affiliation
Exclusion criteria
patients co-infected with human immunodeficiency virus (HIV) or Hepatitis C virus (HCV). Patients treated with interferon, immunosuppressive, or experimental treatment consisting of an unapproved molecule for the treatment of hepatitis B. Patient unable to meet the constraints of the study Patient transplanted Patient with a history of cancer or autoimmune disease within 5 years Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of T cell response by hepatitis B antigen detected in at least one subject. | at day 1 | The method is based on the ELISPOT test. The method measures the cytokine secretion associated with immune activation after stimulation of peripheral blood mononuclear cells |
Secondary
| Measure | Time frame |
|---|---|
| The probability of detection of a positive T cell response in a single measurement | at day 1 |
Countries
France
Outcome results
None listed